glp 1 for cardiovascular disease benefits of glucagon-like peptide-1 receptor agonists Real-World Evidence for GLP-1 Receptor
Description
Whereas the DPP-IV degradation can be avoided by substituting Ala 8 with various amino acids like Gly, Ser, d-Ala, and Aib, 32,37 the degradation by NEP 24.11 is hard to address in a similar manner because of the multiple sites that NEP 24.11 targets (Figure 1)
After that date, it may still be safe and effective, but there is not enough evidence to support beyond that timeframe
The other medical causes of rhabdomyolysis
A 2025 Cochrane review of 18 studies confirmed that semaglutide (Wegovy/Ozempic) results in approximately 10.7% greater weight loss compared to placebo, with high-certainty evidence [6]
It is a complex, chronic medical condition driven by genetics, hormones, metabolism, environment, and behavior
Wegovy: Specifically approved for long-term weight management and typically prescribed for individuals without diabetes who are overweight or obese
